Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4348438 | 0.85 | HTT (0.55) | HTTALDH1A1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL9179087 | 0.65 | RAB9A (0.50) | ALDH1A1RAB9AKMT2A | |
| SCHEMBL9384223 | 0.65 | DDAH1 (0.58) | HTTALDH1A1LMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL19095412 | 0.61 | LMNA (0.52) | ALDH1A1LMNASMN1; SMN2RAB9AMAPT | |
| SCHEMBL8501957 | 0.61 | PARP1 (0.60) | ALDH1A1RAB9A | |
| SCHEMBL2489613 | 0.60 | HTT (0.49) | HTTALDH1A1LMNAL3MBTL1CTDSP1 | |
| SCHEMBL1586540 | 0.60 | PARP1 (0.55) | ALDH1A1RAB9A | |
| SCHEMBL6081732 | 0.60 | PDE10A (0.44) | HTTALDH1A1LMNASMN1; SMN2RAB9A | |
| SCHEMBL2767091 | 0.60 | ALDH1A1 (0.47) | HTTALDH1A1LMNASMN1; SMN2RAB9A | |
| SCHEMBL4288877 | 0.60 | PDE10A (0.44) | HTTALDH1A1LMNASMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277236-A1 | METHOD FOR INHIBITING MMP-9 DIMERIZATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277236-A1 | METHOD FOR INHIBITING MMP-9 DIMERIZATION | MMP9, MMP10, MMP2 | HTT 3048/4885ALDH1A1 2458/4885LMNA 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.